The impacts of parenteral vitamin B1, B6, B12 on hemoglobin levels in chronic kidney disease patients undergoing hemodialysis

Abstract

Chronic kidney disease is a disorder of renal function and structure. The glomerular filtration rate was below the normal value and less than 60 ml/minute /1.73 m2 for more than 3 months. Patients with chronic kidney disease have erythropoietin in small amounts, and cause anemia. Vitamin B1 acts as oxidative decarboxylation reactions, B6 necessary to heme synthesis, and B12 converts homocysteine to methionine. This study aims to measure the impacts of parenteral vitamin B1, B6, B12 on hemoglobin level in chronic renal disease patients undergoing hemodialysis at Bethesda Hospital Yogyakarta and Panti Rapih Hospital Yogyakarta. The design of this study was one group pretest-posttest using secondary data from lab results from medical records. Data were collected from 117 patients using consecutive sampling methods at Bethesda Hospital Yogyakarta and Panti Rapih Hospital Yogyakarta in March 2019. The treatment given was parenteral vitamin B1, B6, B12 twice a week with a dose of 2 ml. Vitamin B was given intravenously after each hemodialysis. Hemoglobin levels were measured 3 times on 1st visit (before vitamin B administration), 2nd visit (after vitamin B administration), and 3rd visit (after vitamin B administration). There were significant differences of hemoglobin levels on 2nd visit compared to 1st visit (p = 0,000); 3rd visit compared to 1st visit (p = 0,000) and 3rd visit compared to 2nd visit (p = 0.010). Parenteral vitamin B1, B6, B12 gave significant impacts on hemoglobin level and was safe for chronic kidney disease patients undergoing hemodialysis.